ALZN - Alzamend Neuro, Inc.

NasdaqCM - NasdaqCM Delayed price. Currency in USD

Alzamend Neuro, Inc.

3500 Lenox Road NE
Suite 1500
Atlanta, GA 30326
United States
844 722 6333

Full-time employees4

Key executives

NameTitlePayExercisedYear born
Mr. Stephan JackmanCEO & Director473.12kN/A1977
Mr. Kenneth S. Cragun CPASr. VP of Fin.N/AN/A1961
Mr. David J. KatzoffChief Financial OfficerN/AN/A1963
Mr. Henry C. W. Nisser Esq.Exec. VP, Gen. Counsel & DirectorN/AN/A1969
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Corporate governance

Alzamend Neuro, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.